Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
— the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA SHANGHAI, China, Aug. 25, 2022 (GLOBE NEWSWIRE) —